JP2005523263A5 - - Google Patents

Download PDF

Info

Publication number
JP2005523263A5
JP2005523263A5 JP2003563565A JP2003563565A JP2005523263A5 JP 2005523263 A5 JP2005523263 A5 JP 2005523263A5 JP 2003563565 A JP2003563565 A JP 2003563565A JP 2003563565 A JP2003563565 A JP 2003563565A JP 2005523263 A5 JP2005523263 A5 JP 2005523263A5
Authority
JP
Japan
Prior art keywords
pharmaceutical composition
inhibitor
fibrosis
composition according
scarring
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2003563565A
Other languages
English (en)
Japanese (ja)
Other versions
JP2005523263A (ja
Filing date
Publication date
Priority claimed from GBGB0202254.9A external-priority patent/GB0202254D0/en
Application filed filed Critical
Publication of JP2005523263A publication Critical patent/JP2005523263A/ja
Publication of JP2005523263A5 publication Critical patent/JP2005523263A5/ja
Pending legal-status Critical Current

Links

JP2003563565A 2002-01-31 2003-01-21 瘢痕化及び繊維症の治療におけるpde5阻害剤の使用 Pending JP2005523263A (ja)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
GBGB0202254.9A GB0202254D0 (en) 2002-01-31 2002-01-31 Prevention of scarring
PCT/IB2003/000134 WO2003063875A1 (en) 2002-01-31 2003-01-21 Use of pde5 inhibitors in the treatment of scarring and fibrosis

Publications (2)

Publication Number Publication Date
JP2005523263A JP2005523263A (ja) 2005-08-04
JP2005523263A5 true JP2005523263A5 (cg-RX-API-DMAC7.html) 2005-12-22

Family

ID=9930135

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2003563565A Pending JP2005523263A (ja) 2002-01-31 2003-01-21 瘢痕化及び繊維症の治療におけるpde5阻害剤の使用

Country Status (8)

Country Link
EP (1) EP1469857A1 (cg-RX-API-DMAC7.html)
JP (1) JP2005523263A (cg-RX-API-DMAC7.html)
BR (1) BR0307410A (cg-RX-API-DMAC7.html)
CA (1) CA2474852A1 (cg-RX-API-DMAC7.html)
GB (1) GB0202254D0 (cg-RX-API-DMAC7.html)
MX (1) MXPA04007430A (cg-RX-API-DMAC7.html)
TW (1) TW200302105A (cg-RX-API-DMAC7.html)
WO (1) WO2003063875A1 (cg-RX-API-DMAC7.html)

Families Citing this family (21)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2004103407A2 (en) * 2003-05-22 2004-12-02 Altana Pharma Ag Composition comprising a pde4 inhibitor and a pde5 inhibitor
JP5070052B2 (ja) 2004-08-17 2012-11-07 ザ・ジョンズ・ホプキンス・ユニバーシティ Pde5阻害剤組成物及び心臓疾患を治療する方法
DE602004022463D1 (de) * 2004-08-19 2009-09-17 Switch Biotech Llc Verwendung eines PDE5-Hemmers zur Behandlung und Vorbeugung von Hypopigmentierungsstörungen
WO2006018088A1 (en) * 2004-08-19 2006-02-23 Switch Biotech Ag Use of a pde 5 inhibitor for treating and preventing hypopigmentary disorders
WO2006074443A2 (en) * 2005-01-07 2006-07-13 The Johns Hopkins University Pde5 inhibitor compositions and methods for immunotherapy
DE102005001989A1 (de) * 2005-01-15 2006-07-20 Bayer Healthcare Ag Intravenöse Formulierungen von PDE-Inhibitoren
US20090215782A1 (en) * 2005-04-18 2009-08-27 Carlo Foresta Use of PDE-5 Inhibitors for Endothelial Repair of Tissues Impaired by Trauma or Disease
EP1888074B1 (en) * 2005-06-10 2011-12-21 Dong-A Pharmaceutical Co., Ltd. Agent for the prevention and treatment of liver diseases containing pyrazolopyrimidine derivative
AR079451A1 (es) 2009-12-18 2012-01-25 Nycomed Gmbh Compuestos 3,4,4a,10b-tetrahidro-1h-tiopirano[4,3-c]isoquinolina
EP2556820A4 (en) * 2010-04-05 2015-01-21 Sk Chemicals Co Ltd COMPOSITION CONTAINING PDE5 INHIBITOR FOR MITIGATION OF SKIN WRINKLES
ES2549979T3 (es) 2010-05-26 2015-11-03 Adverio Pharma Gmbh El uso de estimuladores de la sGC, activadores de la sGC, solos y en combinaciones con inhibidores de la PDE5 para el tratamiento de esclerosis sistémica (EcS)
CN103826638B (zh) * 2011-09-09 2015-11-25 Sk化学公司 含有pde5 抑制剂的减少皮肤皱纹的组合物
AT512084A1 (de) 2011-10-20 2013-05-15 Univ Wien Tech Diazabicyclo- und diazaspiro-alkanderivate als phosphodiesterase-5 inhibitoren
US9789126B2 (en) 2012-12-21 2017-10-17 Mayo Foundation For Medical Education And Research Methods and materials for treating calcific aortic valve stenosis
EP2992885A3 (en) * 2014-09-02 2016-05-18 Jansfat Biotechnology Co., Ltd. Method for inhibiting a liver disease
WO2018167689A1 (en) 2017-03-14 2018-09-20 Atir Holding S.A. Topical formulation for the treatment of pigmented skin
EP3595622B1 (en) 2017-03-14 2023-01-11 Atir Holding S.A. Use of heterocyclic compounds in the treatment of pigmented skin
MX2017016930A (es) * 2017-12-19 2019-06-20 Malesil Research & Tech Llc Uso del maleato de sildenafil en el tratamiento de ulceras de pie diabetico.
MX2021012409A (es) 2019-04-10 2021-11-12 Mayo Found Medical Education & Res Metodos y materiales para el tratamiento dependiente del genero de la disfuncion cardiovascular.
CN112773898A (zh) 2019-11-11 2021-05-11 广州华真医药科技有限公司 磷酸二酯酶5抑制剂在制备抗纤维化疾病药物中的应用
WO2023018972A1 (en) * 2021-08-13 2023-02-16 Mezzion Pharma Co., Ltd. Methods and compositions for treating fibrotic liver conditions, using udenafil compositions

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6331543B1 (en) * 1996-11-01 2001-12-18 Nitromed, Inc. Nitrosated and nitrosylated phosphodiesterase inhibitors, compositions and methods of use
US5965501A (en) * 1997-03-28 1999-10-12 Lever Brothers Company, Division Of Conopco, Inc. Personal washing bar compositions comprising emollient rich phase/stripe
AU5067098A (en) * 1997-11-26 1999-06-15 Mochida Pharmaceutical Co., Ltd. Pyridocarbazole derivatives with cgmp-pde inhibitory activity
ZA9810766B (en) * 1997-11-28 1999-05-25 Mochida Pharm Co Ltd Novel compounds having cgmp-pde inhibitory activity
GB9909135D0 (en) * 1999-04-22 1999-06-16 Univ Wales Medicine Cystic fibrosis medicaments
CA2323008C (en) * 1999-10-11 2005-07-12 Pfizer Inc. Pharmaceutically active compounds
GB9930570D0 (en) * 1999-12-23 2000-02-16 Pfizer Ltd Therapy

Similar Documents

Publication Publication Date Title
JP2025069304A5 (cg-RX-API-DMAC7.html)
JP2023166406A5 (cg-RX-API-DMAC7.html)
RU2335493C2 (ru) Производные хинолина в качестве ингибиторов фосфодиэстеразы
JP2023088944A5 (cg-RX-API-DMAC7.html)
AU2001282988B2 (en) Methods for treating atopic disorders
WO2003099223A3 (en) Copper lowering treatment of inflammatory and fibrotic diseases
JP2007511486A5 (cg-RX-API-DMAC7.html)
JP2023504415A5 (cg-RX-API-DMAC7.html)
JP7525868B2 (ja) アルカリ性化剤による血液浄化
UY28958A1 (es) Nuevos derivados de piridazin-3(2h)-ona
WO2005082863A3 (en) 1,4 diaryl-dihydropyrimidin-2 ones and their use as a human neutrophil elastase inhibitors
JP2005515964A5 (cg-RX-API-DMAC7.html)
WO2007109118A3 (en) RECOMBINANT HUMAN CC 10 (rhCC10) FOR TREATMENT OF RESPIRATORY DISORDERS
HU228927B1 (en) Novel combination of non-sedative anti-histamines containing substances which influence the action of leukotriene, for treating rhinitis, or conjunctivitis
JP2015057436A5 (cg-RX-API-DMAC7.html)
JP2006518387A5 (cg-RX-API-DMAC7.html)
CO5550426A2 (es) Novedoso metodo terapeutico
JP2006512324A5 (cg-RX-API-DMAC7.html)
JP2002528502A5 (cg-RX-API-DMAC7.html)
JP2023076632A5 (cg-RX-API-DMAC7.html)
JP2009518415A5 (cg-RX-API-DMAC7.html)
JP2004505036A5 (cg-RX-API-DMAC7.html)
JP2008523102A5 (cg-RX-API-DMAC7.html)
RU2007107915A (ru) Лекарственные средства для лечения хронического респираторного заболевания
JP2020516689A5 (cg-RX-API-DMAC7.html)